Table 3.

Production and application of IgY antibodies specific to A. baumannii.

Immunogen	Activity/Properties	Reference
Formaldehyde-fixed strains of A. baumannii (ATCC BAA1605 and clinically isolated strain)	Murine model; intraperitoneal injection lowered mortality of infected mice, decreased TNF-α and IL-1β, reduced inflammation of the lung tissue	Shi et al. (42)
Formaldehyde-fixed A. baumannii, recombinant OmpA and recombinant Omp34 proteins	Murine pneumonia model; protection against A. baumannii infection (with OmpA as a most potent antigen)	Jahangiri et al. (43)
Formaldehyde-fixed A. baumannii, recombinant OmpA and recombinant Omp34 proteins	Murine pneumonia model; intranasal delivery therapeutic effect in the murine pneumonia model	Jahangiri et al. (44)
Recombinant Omp34L3X5 and recombinant Omp34 proteins	Murine model; intranasal delivery protection against A. baumannii infection	Maghaddam et al. (45)
Bap recombinant protein	Murine model; intranasal delivery anti-Bap IgY reduces mortality caused by pneumonic infection when administered prophylactically	Ranjbar et al. (46)
Inactivated standard and multidrug-resistant A. baumannii cells	Murine model; IgY of 20 mg/ml (150 μl per 10 g of body weight) 24 h before inoculation and 250 μl per 10 g of body weight daily for 5 days significant mortality reduction	Zhen et al. (47)

If not specified in the Activity/Properties column, then FCA/FIA was used as an adjuvant.